FLAIR™ Delivery System Study (FLAIR DS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00614315
Recruitment Status : Completed
First Posted : February 13, 2008
Results First Posted : October 6, 2010
Last Update Posted : February 28, 2017
Information provided by (Responsible Party):
C. R. Bard

Brief Summary:
The objective of this clinical study is to evaluate the performance of the Optimized FLAIR™ Delivery System.

Condition or disease Intervention/treatment Phase
Constriction, Pathologic Device: FLAIR™ Endovascular Stent Graft Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Observational Study of the FLAIR™ Endovascular Stent Graft Optimized Delivery System
Study Start Date : December 2007
Actual Primary Completion Date : February 2008
Actual Study Completion Date : February 2008

Arm Intervention/treatment
Experimental: FLAIR Endovascular Stent Graft and Delivery System Device: FLAIR™ Endovascular Stent Graft
The FLAIR™ Endovascular Stent Graft is designed to treat venous anastomotic stenoses of AV access grafts, providing both structural support of the site following angioplasty (stent), and a barrier to locally recurrent flow-limiting neointimal tissue growth (covering/graft).

Primary Outcome Measures :
  1. Technical Success for Delivery [ Time Frame: Measured at the time of implantation (Day 0) ]
    defined as deployment of the implant to the intended location, assessed at the time of the index procedure.

Secondary Outcome Measures :
  1. Number of Device/Procedure-related Adverse Events(Safety of Delivery) [ Time Frame: Index Procedure to 30 days ]
    Device/Procedure-related adverse events from the index procedure through 30 days post procedure

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The subject is either a male or non-pregnant female ≥ 18 years old.
  • The subject has been properly informed about the study per IRB requirements, and has signed and dated the IRB-approved ICF.
  • The subject is willing to comply with the protocol requirements and can be contacted by telephone.
  • The subject has a synthetic AV access graft located in an arm that has been implanted for > 30 days and has undergone at least one successful dialysis session prior to the index procedure.
  • Angiographic evidence indicates that the subject has a stenosis of >50% located at the graft-vein anastomosis of the subject's synthetic AV access graft.
  • The target lesion is estimated to be ≤ 7 cm in length by angiography prior to performance of any interventional procedures.
  • The entire target lesion is located within 7 cm of the graft-vein anastomosis, as verified by angiography, such that approximately 1 cm of the FLAIR™ Endovascular Stent Graft will extend into non-diseased vein and approximately 1 cm but no more than 2 cm of the FLAIR™ Endovascular Stent Graft will extend into non-diseased AV graft.
  • Graft diameter at the deployment site is between 5 mm and 8 mm, as verified by angiography.
  • Full expansion of an appropriately sized angioplasty balloon, in the operator's judgment, can be achieved during primary angioplasty.

Exclusion Criteria:

  • The subject has a life expectancy of < 6 months.
  • The presence of a previously placed stent and/or stent graft located in the treatment area. The treatment area is defined as the entire target lesion and 1 cm of landing zone into both non-diseased AV graft and non-diseased vein.
  • The subject has an infected AV access graft or other infection.
  • The location of the target lesion would require that the FLAIR™ Endovascular Stent Graft be deployed fully across the elbow joint.
  • The location of the target lesion would require that the FLAIR™ Endovascular Stent Graft cross an angle (between the outflow vein and synthetic AV access graft) that is > 90 degrees.
  • The subject has an uncorrected blood coagulation disorder.
  • The subject has a known allergy or sensitivity to contrast media which cannot be adequately pre-medicated.
  • Subject is currently enrolled or scheduled to be enrolled in other investigations that conflict with follow-up testing or confounds data in this trial.
  • The subject has a known hypersensitivity to nickel-titanium.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00614315

United States, Connecticut
Connecticut Image Guided Surgery
Fairfield, Connecticut, United States, 06825
Sponsors and Collaborators
C. R. Bard
Principal Investigator: Melvin Rosenblatt, M.D. Connecticut Image Guided Surgery

Responsible Party: C. R. Bard Identifier: NCT00614315     History of Changes
Other Study ID Numbers: BPV-07-001
First Posted: February 13, 2008    Key Record Dates
Results First Posted: October 6, 2010
Last Update Posted: February 28, 2017
Last Verified: January 2017

Additional relevant MeSH terms:
Constriction, Pathologic
Pathological Conditions, Anatomical